Literature DB >> 24681343

FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?

Alexandre Liccioni1, Maria Reig1, Jordi Bruix2.   

Abstract

Entities:  

Keywords:  BCLC; HCC; Treatment

Mesh：

Year:  2014        PMID： 24681343     DOI： 10.1016/j.jhep.2014.03.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

Review 1.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

2.  Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.

Authors:  Jun Li Ma; Shan Zeng; Yan Zhang; Gan Lu Deng; Hong Shen
Journal:  Tumour Biol       Date:  2015-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.